Can-Fite BioPharma

[On Demand]
Search General Info
Search Education
Search Partnering Companies
The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
Ticker:
CANF
Exchange:
NYSE
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2000
Main Therapeutic Focus:
Lead Product in Development:
Piclidenoson
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Piclidenoson: Psoriasis & COVID-19; Namodenoson: Liver Cancer & NASH; CF602 - Sexual Dysfunction
Speaker
photo
VP of Business Development
Can-Fite BioPharma Ltd.